```html

Jackson–Moray Disease (Autoimmune Hepatitis Type 2)

Overview

Jackson‑Moray disease, more formally known as autoimmune hepatitis type 2 (AIH‑2), is a chronic inflammatory liver disorder in which the immune system mistakenly attacks healthy liver cells. AIH‑2 is distinguished from the more common type 1 by the presence of specific auto‑antibodies (anti‑liver‑kidney‑microsomal type 1, abbreviated anti‑LKM‑1, and/or anti‑liver‑cytosol type 1, anti‑LC‑1).

The disease can progress rapidly to fibrosis or cirrhosis if left untreated, but most patients respond well to immunosuppressive therapy. Early recognition is crucial, especially because AIH‑2 frequently presents in children and adolescents.

Who is affected?

• Age: Primarily children and teenagers; the median age at diagnosis is 8–12 years, though cases have been reported in infants and adults.
• Sex: A slight female predominance (≈ 55 % female) is seen, but the gender gap is narrower than in AIH‑1.
• Geography: Reported worldwide with higher incidence in Northern Europe and North America; exact prevalence is difficult to ascertain because many cases are mis‑diagnosed.

Prevalence & Incidence

Estimates for all forms of autoimmune hepatitis range from 1 to 2 per 100,000 people (CDC). AIH‑2 accounts for roughly 10–20 % of these cases, translating to about 0.1–0.4 per 100,000 individuals. In pediatric hepatology centers, AIH‑2 may represent up to 30 % of all autoimmune hepatitis diagnoses.

Symptoms

Symptoms can be subtle at first and often mimic other liver disorders. The presentation may be acute, sub‑acute, or chronic.

• Fatigue and malaise – persistent tiredness not relieved by rest.
• Jaundice – yellowing of the skin and sclera due to elevated bilirubin.
• Abdominal discomfort – usually a dull, right‑upper‑quadrant ache.
• Pruritus (itching) – caused by bile salt accumulation.
• Dark urine & pale stools – reflect impaired bilirubin excretion.
• Loss of appetite & weight loss.
• Fever – low‑grade, often present during acute flares.
• Joint or muscle aches – extra‑hepatic autoimmune features.
• Elevated liver enzymes – often discovered incidentally on routine labs.
• Hepatomegaly – palpable enlargement of the liver on physical exam.
• Signs of chronic liver disease (if disease is advanced): spider angiomas, palmar erythema, ascites, or hepatic encephalopathy.

Causes and Risk Factors

AIH‑2 is an autoimmune condition, meaning the immune system targets the liver for unknown reasons. The exact cause is multifactorial:

Genetic predisposition

• HLA alleles: Strong association with HLA‑DRB1*03 and HLA‑DRB1*07 in many populations (NIH).
• Family history: First‑degree relatives with other autoimmune diseases (e.g., type 1 diabetes, thyroiditis) have a modestly increased risk.

Environmental triggers

• Viral infections: Hepatitis A, EBV, CMV, and hepatitis C have been reported as preceding events that may “unmask” the disease.
• Medications & herbs: Rarely, drugs such as minocycline or herbal supplements can act as a trigger in genetically susceptible individuals.
• Toxins: No definitive toxin link, but some case series suggest exposure to industrial solvents may play a role.

Other risk factors

• Being under 18 years old (peak incidence in childhood).
• Female sex (modest increase).
• Co‑existing autoimmune disorders (e.g., celiac disease, autoimmune thyroiditis).

Diagnosis

Diagnosis requires a combination of clinical, laboratory, and histologic criteria. The 1999 International Autoimmune Hepatitis Group (IAIHG) scoring system (updated in 2008) remains the reference.

Key diagnostic steps

1. History & physical exam – focus on liver‑related symptoms, past infections, medication use, and family autoimmune history.
2. Blood tests
   • Elevated aminotransferases (ALT, AST) – often >10 × upper limit of normal.
   • Hypergammaglobulinemia, especially IgG elevation.
   • Auto‑antibody profile:
     • Anti‑LKM‑1 – present in 70–80 % of AIH‑2.
     • Anti‑LC‑1 – less common but highly specific.
   • Exclusion of viral hepatitis (HBsAg, anti‑HBc, HCV RNA), Wilson disease, and metabolic liver disorders.
3. Liver imaging – Ultrasound, CT, or MRI to rule out biliary obstruction, masses, or fatty liver disease.
4. Liver biopsy – Gold standard. Typical findings:
   • Interface hepatitis (piecemeal necrosis) with lymphoplasmacytic infiltrate.
   • Bridging necrosis and/or fibrosis (stage dependent).
   • Minimal steatosis; absence of granulomas or eosinophils (helps exclude other causes).
5. Scoring – Apply the IAIHG criteria; a score ≥15 (pre‑treatment) strongly supports AIH‑2.

Special considerations for children

Because pediatric patients often present with acute liver failure, a rapid work‑up (including viral PCR, metabolic panels, and urgent biopsy) is essential. The European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) recommends initiating corticosteroid therapy promptly when AIH‑2 is strongly suspected, even before biopsy results are available.

Treatment Options

Goal: suppress immune attack, normalize liver enzymes, prevent progression to cirrhosis, and maintain remission with the lowest possible medication burden.

First‑line pharmacotherapy

• Prednisone (or prednisolone) – Initial dose 2 mg/kg/day (max 60 mg) for 2–4 weeks, then taper based on response.
• Azathioprine – 1–2 mg/kg/day started after the first week of steroids to allow steroid tapering; acts as a steroid‑sparing agent.

Combination therapy achieves remission in 80–90 % of patients (Cleveland Clinic).

Second‑line / steroid‑sparing agents

• Mycophenolate mofetil (MMF) – 600–1000 mg/m² twice daily; useful in azathioprine intolerance.
• Bud­esonide – Low‑first‑pass steroid used in non‑cirrhotic adults; less systemic side‑effects.
• Calcineurin inhibitors (tacrolimus, cyclosporine) – Reserved for refractory disease.

Treatment of acute severe or fulminant AIH‑2

High‑dose IV methylprednisone (30 mg/kg/day, max 1 g) for 3‑5 days, followed by oral taper, is standard. If no improvement within 7‑10 days, early referral for liver transplantation should be considered.

Lifestyle and supportive measures

• Vaccinations: Hepatitis A & B, annual flu, pneumococcal; essential because immunosuppression increases infection risk.
• Alcohol avoidance: Even modest intake can accelerate liver injury.
• Balanced diet: Adequate protein, limited saturated fat, and sufficient calories to support growth in children.
• Bone health: Calcium + vitamin D supplementation and weight‑bearing exercise to counteract steroid‑induced osteoporosis.

Living with Jackson–Moray Disease (autoimmune hepatitis type 2)

Long‑term management focuses on medication adherence, monitoring, and quality of life.

Medication adherence

• Set daily reminders (phone alarms, pill boxes).
• Never stop steroids abruptly; taper under physician guidance.
• Report side‑effects (e.g., mood changes, excessive bruising) promptly.

Routine monitoring

Parameter	Frequency
Liver enzymes (ALT, AST)	Every 2–4 weeks until stable, then every 3–6 months
Serum IgG	Every 3 months
Complete blood count & metabolic panel	Every 3 months (more often if on azathioprine)
Bone density (DEXA)	Every 1‑2 years if on long‑term steroids
Ultrasound for fibrosis	Every 1‑2 years or if clinical worsening

Psychosocial support

• Connect with support groups (e.g., Autoimmune Hepatitis Association).
• School accommodations for children (extra nap time, flexibility for medical appointments).
• Consider counseling for anxiety/depression, which are more common in chronic liver disease.

Travel and daily activities

• Carry a medication list and emergency contact card.
• Stay hydrated and avoid raw or undercooked shellfish in regions with high hepatitis A prevalence.
• Plan for medication storage in case of temperature extremes (azathioprine should be kept cool).

Prevention

Because AIH‑2 is autoimmune, primary prevention is not currently possible. However, steps can be taken to reduce triggers and complications:

• Prompt treatment of viral infections (e.g., hepatitis A vaccination).
• Avoid unnecessary hepatotoxic drugs and herbal supplements.
• Maintain a healthy weight to prevent non‑alcoholic fatty liver disease, which can worsen inflammation.
• Adhere to recommended vaccination schedules, especially before initiating immunosuppression.

Complications

If disease activity is not adequately controlled, the following complications may arise:

• Cirrhosis – Scarring that can lead to portal hypertension, variceal bleeding, and liver failure.
• Hepatocellular carcinoma (HCC) – Risk increases markedly once cirrhosis is established (≈ 1–2 % per year).
• Liver transplant necessity – Required in <10 % of pediatric AIH‑2 patients who develop fulminant liver failure.
• Medication‑related side effects – Steroid‑induced diabetes, hypertension, cataracts; azathioprine‑related myelosuppression; MMF‑related GI upset.
• Infections – Immunosuppression predisposes to bacterial, viral, and opportunistic infections (e.g., pneumocystis).
• Prenatal concerns – Women with AIH‑2 planning pregnancy need careful medication adjustment to avoid fetal toxicity.

When to Seek Emergency Care

---

For personalized advice, always discuss your specific situation with a hepatologist or gastroenterologist experienced in autoimmune liver disease. This guide provides general information and does not replace professional medical care.

```